Bevacizumab Plus Chemotherapy Receives FDA Approval for Ovarian Cancer

Article

Bevacizumab (Avastin), an intravenous drug manufactured by Genentech, has received US Food and Drug Administration (FDA) approval for the treatment of platinum-sensitive, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer based on two phase III clinical trial results.1

The clinical trials, GOG-0213 and OCEANS, both reveled positive outcomes for women with these cancers. Specifically, GOG-0213’s study results, which demonstrated that women experienced a 5-month increase in overall survival with the addition of bevacizumab to chemotherapy, and both GOG-0213 and OCEANS revealed improved progression-free survival times.

Bevacizumab), a biologic antibody, is intended to interrupt tumor angiogenesis (blood vessel formation). This is accomplished by binding to the protein VEGF (vascular endothelial growth factor) in an attempt to stop the tumor’s blood supply and decrease metastasis.

The angiogenesis inhibitor will now be available to women in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by bevacizumab only after completion of treatment with the other combination of drugs. It is already available to treat other gynecologic malignancies, including certain cervical cancers and platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancers.1

In addition to the side effects of bevacizumab) in other trials such as epistaxis, headache, hypertension, nasal inflammation, proteinuria, taste changes, dry skin, rectal bleeding, tear production disorder, back pain, and exfoliative dermatitis, the GOG-0213 and OCEANS study participants also experienced fatigue, febrile neutropenia, hyponatremia, extremity pain, thrombocytopenia, proteinuria, hypertension, and headache.

Along with the aforementioned side effects, bevacizumab is also associated with serious and potentially fatal gastrointestinal perforation, delayed or complicated wound healing, severe bleeding, fistula formation, stroke, heart problems, proteinuria, renal dysfunction, blood clots, severe hypertension, posterior reversible encephalopathy syndrome, infusion reactions, ovarian failure with impaired fertility, and fetal risks.

References:

1. Genentech, Inc. FDA Approves Genentech’s Avastin® (Bevacizumab) Plus Chemotherapy for a Specific Type of Advanced Ovarian Cancer. Press release. 2016 Dec 6.

Related Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Ritu Salani, MD, highlights the possible benefit of a novel targeted therapy and autologous tumor vaccine in patients with platinum-resistant ovarian cancer, and in the maintenance setting after treatment for platinum-sensitive disease.
Related Content